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At Glance Summary  
Obstructive sleep apnoea is known to be common in patients with type 2 diabetes. Previous studies 
showed a cross-sectional association between OSA and diabetes-related microvascular 
complications (such as nephropathy and neuropathy). There are no published studies assessing the 
relationship between OSA and diabetic retinopathy longitudinally. Our study is the first to 
prospectively examine the impact of OSA on diabetic retinopathy. Our study showed that 
obstructive sleep apnoea was independently associated with maculopathy and sight threatening 
retinopathy in patients with Type 2 Diabetes and that OSA is associated with the development of 
advanced (pre-proliferative and proliferative) retinopathy longitudinally over approximately 4 years 
period in patients with Type 2 diabetes. 
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Abstract 
Aims: To assess the relationship between obstructive sleep apnoea (OSA) and diabetic retinopathy 
(DR) in patients with type 2 diabetes (T2D) and to assess whether OSA is associated with its 
progression). 
Methods: A longitudinal study from diabetes clinics in two UK hospitals was conducted. Patients 
known to have any respiratory disorder (including OSA) were excluded. DR was assessed using 
2x45degrees retinal images per eye. OSA was assessed using a home-based, multi-channel 
cardiorespiratory device.  
Results: 230 patients were included. Sight threatening DR (STDR) and OSA prevalence was 36.1% 
and 63.9% respectively. STDR prevalence was higher in patients with OSA (OSA+) vs. those without 
(OSA-) (42.9% vs. 24.1% (p0.004). After adjustment for confounders, OSA remained independently 
associated with STDR (OR 2.3, 95%CI 1.1-4.9, p=0.04).  
After a median (IQR)follow-up of 43.0 (37.0-51.0) months, OSA+ patients were more likely to 
develop pre-/proliferative DR compared to OSA- patients (18.4% vs. 6.1%, p=0.02). After adjustment 
for confounders, OSA remained an independent predictor of progression to pre-/proliferative DR 
(OR 5.2, 95%CI 1.2-23.0, p=0.03). Patients who received continuous positive airway pressure (CPAP) 
treatment were significantly less likely to develop pre-/proliferative DR. 
Conclusions: OSA is associated with STDR in patients with T2D. OSA is an independent predictor for 
the progression to pre-/proliferative DR. CPAP treatment was associated with reduction in pre-
/proliferative DR. Interventional studies are needed to assess the impact of OSA treatment on STDR. 
Abstract word count: 226 
Key words: obstructive sleep apnoea, diabetic retinopathy, maculopathy 
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Introduction 
Diabetic retinopathy (DR), affects 40-50% of patients with diabetes and is a leading cause of 
blindness in the Western world and results in significant morbidity and economic 
burden.1;2Important  risk factors include age, poor glycaemic control , hypertension, 
diabetes  duration, dyslipidaemia and genetic  factors.1;3Although the precise aetiology of DR 
remains debated, increased inflammation, oxidative stress, and activation of multiple pathways, are 
thought to result in functional and/or structural defects involving the microvasculature. These will  
increase vascular permeability (which can lead to macular oedema) or cause ischaemia leading to 
increased vascular endothelial growth factor (VEGF) and neovascularisation.1;4Despite improvements 
in the control of metabolic and vascular risk factors, DR remains very common.5and a significant 
proportion of DR progresses to sight-threatening diabetic retinopathy (STDR)1. Hence, improved 
understanding of the pathogenesis of DR is important in order to identify new treatment 
targets/strategies. 
 
Obstructive sleep apnoea (OSA) is very common in patients with type 2 diabetes (T2D).6-10. We have 
previously reported that OSA is associated with peripheral neuropathy, nephropathy and estimated 
glomerular filtration (eGFR) decline in patients with T2D independently of obesity.10;11We have also 
shown that OSA is independently associated with increased nitrosative and oxidative stress and 
impaired microvascular regulation in patients with T2D10.T2D is also a risk factor for severe 
nocturnal  hypoxaemia.12 Hence, it seems reasonable to speculate that OSA could play a  role in the 
pathogenesis STDR particularly since OSA is also associated with many of the pathophysiological 
deficits  found in DR (including inflammation, oxidative stress and increased VEGF).13-18 
The  aim of this study was therefore to determine the interrelationships of OSA and STDR in subjects 
with T2D and assess whether OSA is associated with DR progression. Some of the findings of this 
paper were presented in the form of abstracts.19 
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Methods: 
We conducted an observational cross-sectional study which was converted to a longitudinal 
prospective study in subjects with T2D. Patients with respiratory disease (including pre-diagnosed 
OSA), end-stage renal disease or non-diabetic retinopathy were excluded (Figure 1). Patients were 
recruited consecutively from the out-patient diabetes departments of two secondary care hospitals 
in the UK (Birmingham Heartlands Hospital and Royal Stoke University Hospital). The project was 
approved by the Warwickshire Research Ethics Committee (REC number 08/H1211/145), and all 
patients provided written informed consent. 
OSA was assessed by a single overnight home-based cardio-respiratory study using a portable multi-
channel device (Alice PDX, Philips Respironics).  Sleep studies were scored in accordance with the 
American Academy of Sleep Medicine (AASM) guidelines using the hypopnea definition of ≥ 4% 
oxygen desaturation and ≥ 30% reduction in nasal air flow signal.20 Sleep studies of <4 hours of 
adequate recordings were repeated and if the quality remained poor they were excluded from 
analysis. All sleep studies were double scored manually and further scoring was performed in cases 
of discrepancy (by a consultant in sleep medicine, AA). An apnoea hypopnea index (AHI) ≥ 5 
events/hour was consistent with OSA diagnosis.21 OSA severity was assessed based on the AHI and 
the oxygen desaturation index (ODI) based on 4% oxygen desaturation. OSA was classified into mild, 
moderate and severe based on AHI ≥ 5 - < 15, 15 - < 30 and ≥ 30 events/h respectively. Data 
regarding continuous positive airway pressure (CPAP) treatment was collected as part of routine 
care as all patients with moderate to severe OSA at baseline were referred to the sleep clinic in the 
respective NHS trusts for further assessment and decisions regarding treatment. CPAP was offered 
to all patients with moderate to severe OSA.  CPAP usage data were obtained from the electronic 
patients record approximately 2.5 years following the OSA diagnosis and referral to the sleep clinic.  
CPAP usage > 4 hours/night on 70% of days was considered to indicate compliance.22  
DR/STDR was assessed using 2x45 degrees digital retinal images per eye as per the English National 
Screening programme guidelines (Table 1).23 The retinal images included in this study were obtained 
during routine care as patients with diabetes in England are invited to have retinal images as part of 
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the national screening program once a year. All retinal images were graded at least twice with 
further grading performed in cases of discrepancy by a consultant ophthalmologist. Patients with 
ungradable images were examined by a consultant ophthalmologist. STDR was defined as the 
presence of pre-proliferative or proliferative DR,  maculopathy or photocoagulation (Table 1).23 
Advanced DR was defined as having pre-proliferative (R2) or proliferative (R3) DR. 
The cross-sectional baseline recruitment analysis designed to explore the relationship between OSA 
and STDR was conducted using data collected between 2009 and 2010.  In order to explore the 
impact of OSA on the rate of progression of STDR, a longitudinal analysis using retinal images from 
one of the study centres was performed in 2014. All patients who had at least one retinal screening 
following the baseline visit were included in the longitudinal analysis. All images between baseline 
and end of follow-up were reviewed and the worst retinal grades prior to receiving DR treatment 
were included in the analysis. Progression to maculopathy was assessed by examining the 
progression from no maculopathy (M0) to maculopathy (M1) after excluding patients with M1 at 
baseline. Progression to advanced DR was examined by assessing the progression from no (R0) or 
background (R1) DR to pre-proliferative (R2) or proliferative (R3) DR after excluding patients who 
had R2 or R3 at baseline. In analysing retinal imaging grading, the worst eye grade was used. 
Sleep study scorers were blinded to patient’s DR grade and retinal graders were blinded to the 
patient’s OSA status. All data (apart from the retinal images) were obtained during one-to-one 
interview. 
Data analysis was performed using SPSS 22.0 software (SPSS Inc, Chicago, USA). Data are presented 
as mean (SD) or median (IQR) depending on data distribution. Independent continuous variables 
were compared using the Student’s t-test or the Mann-Whitney test.  Categorical variables were 
compared using the Chi-squared test. Correlations between continuous variables were performed 
using the Pearson or Spearman tests. All statistical tests conditions/assumptions were adhered to 
throughout the analysis. 
To assess whether OSA and/or hypoxaemia measures are independently associated with STDR, 
Advanced DR and maculopathy, multiple logistic regression (forced entry method) was used, in 
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which STDR, advanced DR and maculopathy status were the outcome measures respectively and 
OSA and other possible confounders were the covariates.  
To assess the predictors of DR progression, multiple logistic regression was used with progression to 
maculopathy and progression to advanced DR as the outcomes and OSA and other confounders as 
the covariates (please see the results for a full list of the covariates). 
To assess the relationship between OSA severity and the outcome measures in the cross sectional 
and longitudinal analysis, tertiles of AHI and ODI were used in the logistic regression models. 
Collinearity was considered in assessing fit of models to data. Based on the tolerance and the VIF 
tests there was no evidence of collinearity. However, based on the condition index there was 
evidence of collinearity with condition index value > 30 but there was no variance proportions > 0.5. 
Sequentially removing variables involved in multicollinearity had limited impact on models estimates 
for the main exposure. Hence, final models presented included variables based on the known 
outcome-related risk factors and/or possible confounders and/or variables that differed between 
patients with and without OSA, regardless of the presence of collinearity. A p value < 0.05 was 
considered significant. 
Results: 
Two hundred and sixty-six patients were recruited, 36 were excluded, leaving 230 patients for 
baseline analysis (Figure 1). Of these 230 patients, 57.0% (n=131) were men and 54.8% (n=126) 
White Europeans and 45.2% (n=104) South Asians. There were no differences between those who 
were included and those excluded in regards to the prevalence of DR, maculopathy or STDR. 
OSA prevalence was 63.9% (n=147). The prevalence of mild, moderate and severe OSA were 37.8% 
(n=87), 14.8% (n=34) and 11.3% (n=26) respectively. STDR prevalence was 36.1 % (n=83), DR 
prevalence was 63.5% (n=146) (R0 36.5% (n=84), R1 48.3% (n=111), R2 6.5% (n= 15), R3 8.7% (n= 
20)). Prevalence of advanced DR was 15.2% (35) and maculopathy prevalence was 31.7% (n=73).  
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The prevalence of OSA was higher in White Europeans. Patients with OSA (OSA+) were older, more 
obese and had higher systolic BP compared to those without OSA (OSA-) (Table 2). The use of 
antihypertensive agents and insulin was higher in OSA+ patients, whilst there were no differences in 
the use of anti-platelet or lipid-lowering therapy (Table 2). 
Cross-sectional analysis 
The prevalence of STDR, advanced DR (R2 or R3) and maculopathy were significantly higher in OSA+ 
patients compared to those without OSA (Table 3).  
OSA and DR; the multivariable analysis 
To assess whether the relationship between OSA and STDR is secondary to or independent of 
possible confounders, logistic regression models were used (Table 4). Despite adjustment, OSA 
remained independently associated with STDR (Table 4). In addition to OSA (OR 2.3, 95%CI 1.1-4.8, 
p=0.03); diabetes duration (OR 1.1, 95%CI 1.0-1.1, p=<0.001), and HbA1c (OR 1.3, 95%CI 1.0-1.7, 
p=0.01) were also independently associated with STDR.  
OSA was also independently associated with maculopathy (OR 2.6, 95%CI 1.2-5.8, p=0.01) (Table 4). 
For the relationship between OSA severity and DR please see online supplement. 
OSA and DR progression: Longitudinal analysis 
We hypothesise that retinopathy progression from background to more advanced stages is 
accelerated by the presence of OSA. Therefore, in order to explore this construct, a longitudinal 
analysis was conducted in 199 patients out of 230 patients as follow up data was available from one 
site only. The average follow up was 43.0 (37.0-51.0)months. There was no significant difference in 
the median (IQR) follow up duration between patients without (n=71) and with OSA (n=122) (45.0 
(37.0-51.0) months vs. 42.5 (36.0-51.0) months respectively, p=0.32). A summary of follow-up 
duration and DR progression in patients with R0 at baseline in patients with and without OSA can be 
found in Figure 1 of the online supplement. 
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Examining the progression from R0 or R1 to advanced DR (R2 or R3), 164 cases were available for 
analysis (out of 199) after excluding 29 patients who had advanced DR at baseline and 6 cases of loss 
of follow-up. Out of the 164 patients included in this analysis 66 (40.2%), 60 (36.6%), 19 (11.6%) and 
19 (11.6%) had no, mild, moderate and severe OSA respectively. For the baseline characteristics of 
this population please refer to the online supplement. The proportion of patients progressing to 
advanced DR was higher in OSA+ patients (18.4% (n=18) vs. 6.1% (n=4), p=0.02 for OSA+ and OSA- 
respectively), with similar trends in South Asians (14.0% (n=6) vs. 8.9% (n=4), p=0.45) and White 
Europeans (21.8% (n=12) vs. 0.0% (n=0), p=0.02).  
Data from 129 (out of 199) subjects were available to examine the progression to maculopathy (M0 
to M1) after excluding 65 patients with M1 at baseline and 5 cases of loss of follow-up. There was no 
significant difference in maculopathy progression between OSA+ and OSA- patients (20.8% (n=15) vs. 
19.3% (n=11), p=0.83 for OSA+ and OSA- respectively). 
Similarly, data from 121 patients (out of 199) was available to examine the progression to STDR after 
excluding 74 patients with STDR at baseline and 4 cases of loss of follow-up. The proportion of 
patients progressing to sight threatening DR was not statistically different between OSA+ and OSA- 
patients (20.6% (n=14) vs. 13.2% (n=7), p=0.29 for OSA+ and OSA- respectively) regardless of 
ethnicity (South Asians: 21.2% (n=7) vs. 19.4% (n=7), p=0.86); White Europeans: 20.0% (n=7) vs. 0.0% 
(n=0), p=0.05). 
After adjustment for ethnicity, gender, diabetes duration, age at diabetes diagnosis, systolic blood 
pressure, HbA1c, eGFR, BMI, oral anti-hyperglycaemic agents and insulin use and number of anti-
hypertensive medications (Nagelkerke R2 for the model 0.42), OSA remained an independent 
predictor of progression to advanced DR (OR 5.2, 95%CI 1.2-23.0, p=0.03) (Table 5). There was also a 
dose-effect relationship showing that moderate to severe OSA (vs. no OSA), and tertiles 3 (vs. tertile 
1) of AHI and ODI were significantly associated with progression to advanced DR (Table 5). 
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In order to assess whether differences in follow up might account for the observed relationship 
between OSA and progression to advanced DR, we compared the follow-up duration in patients with 
OSA who progressed and did not progress to advanced DR. We calculated the follow-up based on 
two methods: 1. using the latest available retinal image or clinical data when the data was accessed 
in 2014 as detailed in the methods; 2. Using first mention of progression to advanced DR in 
electronic records or the retinal screening images. The median (IQR) follow-up (based on first 
mention of advanced DR in the records) in patients with OSA who did not progress (n=80) vs. those 
who progressed (n=18) to advanced DR was 44.0 (37.0-51.0) months vs. 32.5 (21.8-42.3) months 
respectively (p=0.006). This data suggest that the follow-up duration was significantly shorter in 
patients with OSA who developed advanced DR compared to those who did not develop advanced 
DR. Compared the follow-up duration (based on the date of the last available record in 2104), we 
found no difference between patients with OSA who did not progress and those who progressed to 
advanced DR 44.0 (37.0-51.0) months vs. 43.5 (35.5-52.5) months respectively (p=0.9). This data 
suggest that our findings are not related to a longer follow-up in patients who had OSA and 
progressed to advanced DR. In addition, adding the follow-up duration (based on the date of last 
available record in 2014) to the regression model did not change our findings (The Nagelkerke R2 
remained 0.42; OR for progression to advanced DR in patients with OSA vs. those without OSA was 
5.2 (95%CI 1.2-23.0, p= 0.03)). Adding the follow-up duration (based on the first mention of 
advanced DR in the records) did not change the results either (Nagelkerke R2 0.5; OR 5.4, 95%CI 1.1-
27.4, p=0.04). Hence, the length of follow-up does explain the associations between OSA and 
progression to advanced DR in our study.  
We also assessed the impact of changes in HbA1c during the follow-up on the association between 
OSA and progression to advanced DR; we found that these associations are independent of changes 
in HbA1c during the follow-up. More details are included in the online supplement 
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CPAP and DR progression 
CPAP lowered the progression to advanced DR and maculopathy, but this was statistically significant 
only in the progression to advanced DR category (please see online supplement for details) 
Discussion: 
This is the first report to examine the relationship between OSA and DR longitudinally. T2D and OSA 
frequently co-exist and can be associated with a range of metabolic and physiological perturbations 
which have also been implicated in the pathogenesis of DR. Our study demonstrates that OSA (even 
when mild) is independently associated with STDR, maculopathy and advanced DR in patients with 
T2D. We have also shown that OSA is an independent predictor of progression to R2 or R3 over 
approximately 4 years period and that CPAP treatment might have a beneficial impact on DR 
progression. 
The population in our report comprises subjects attending large inner city, hospital-based diabetes 
clinics in which the known duration of diabetes was approximately 10 years. Many of the subjects 
already exhibited established diabetes complications (such as albuminuria as indicated in Table 
2).The participant characteristics  are similar to those reported previously from a different region in 
the UK,24 suggesting that the current study sample was representative of the wider T2D population 
in secondary care. However, whether our findings are applicable to patients typically managed in 
primary care and those with a shorter duration of diabetes remains to be examined.   The high 
prevalence of OSA in our sample is consistent with other studies in subjects with T2D.6-9  The 
prevalence of STDR in our cohort (36.1%) is higher than that reported in the literature (5-
15%),1;25reflecting differences in the cohorts and DR risk factors in the various studies. 
OSA+ patients differed from those without OSA in regards to multiple demographic and metabolic 
factors. Nevertheless, the association between OSA and advanced DR remained independent despite 
adjustment for these confounders. STDR, and maculopathy were also associated with mild OSA. This 
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suggests that the adverse impact of OSA in patients with T2D occurs even in patients with mild 
degrees of OSA and it is possible that the impact of mild OSA is magnified in tissue that is already 
predisposed to damage because of chronic hyperglycaemia. This is further exacerbated by the 
increased retinal oxygen requirements during night adaptation; hence, even mild hypoxia can result 
in major adverse consequences to the retina.26 In addition, there was a dose-response relationship in 
the association between OSA and progression to advanced DR as this association was statistically 
significant mainly in patients with moderate to severe OSA and in patients with highest AHI and ODI 
tertiles, suggesting potentially that OSA exacerbated retinal ischaemia which is an integral part of 
the development of pre-proliferative and proliferative DR.  
There are several mechanisms that can link OSA to maculopathy and pre-proliferative and 
proliferative DR. Retinal ischemia in diabetes result in the stimulation of hypoxia-inducible factors 
(HIFs) , which are transcriptional factors that are activated under hypoxic conditions resulting in the 
expression of multiple gene products, including VEGF27. Increased VEGF leads to the development of 
proliferative DR; and retinal ischaemia is the main stimulant of VEGF secretion resulting in 
proliferative retinopathy; and as a result anti-VEGF are currently used in clinical practice to treat 
DR.1;4 The hypoxaemia associated with OSA  has been shown to be associated with increased VEGF, 
which was lowered by CPAP treatment.28 This is particularly important as the retina is particularly 
prone to hypoxic damage during night hours29, which is the same time in which OSA associated 
hypoxaemia occurs. In addition, endothelial dysfunction plays an important role in the development 
of DR and manculopathy; we and others have previously shown that OSA (and its associated cyclical 
oxygen desaturations and disruption in sleep architecture) can lead to the activation of PARP, PKC, 
and the polyol pathway, and increased AGE production, inflammation and oxidative and nitrosative 
stress, all of which can lead to endothelial dysfunction and can contribute to the observed 
associations between OSA and DR in our study.10;30;31 10.  
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In our study, the observed cross-sectional and longitudinal associations between OSA and DR were 
much stronger in White Europeans compare to South Asians. There might be several plausible 
reasons for the observed ethnic differences. South Asians with T2D are known to be at an increased 
risk of DR and STDR compared to White Europeans with T2D.32 Hence, in South Asians there are 
factors other than OSA that result in increased risk of DR in this population compared to White 
Europeans making the impact of OSA on DR in South Asians smaller and hence requiring significantly 
larger sample size to detect. This is supported by our analysis showing that the direction of the 
relationship between OSA and STDR, advanced DR, and maculopathy cross-sectionally and 
longitudinally is similar between South Asians and White Europeans, but the magnitude is greater in 
White Europeans. Another important factor is that we have shown in this cohort previously that OSA 
is less common and less severe in South Asians compared to White Europeans with T2D;33 which 
might also contribute to the weaker relationship between OSA and STDR, maculopathy and 
advanced DR observed in this study in South Asians compared to White Europeans.  
Two previous studies have shown an association between OSA and DR, but there are important 
differences between these studies and ours. These studies were cross-sectional and, unlike ours, a 
longitudinal analysis was not performed. Additionally, the previous studies included highly selected 
populations such as Japanese patients who underwent vitreous surgery34 or only White European 
men;35  Our study was more comprehensive and included patients regardless of their ethnicity, 
gender or  severity of retinopathy. Moreover, in prior reports the diagnosis of DR was based on case 
records rather than using retinal images as utilized in our study.34 OSA assessment also differed 
between the studies; one study used pulse oximetry  to diagnose OSA,34whilst the other used a 
complex multi-step approach based on questionnaires followed by pulse oximetry on a selected 
subgroup.35 We performed a more in depth assessment using a multi-channel device in all the study 
participants. Critically, the previous studies did not adjust for important possible confounders such 
as blood pressure, BMI, medication use, or used suboptimal measures, such as self-reported 
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BMI.34;35 In contrast, our extensive data ascertainment allowed us to adjust for a wide range of 
possible confounders.  
Although OSA has been associated with several other ocular pathologies in patients without 
diabetes; 36-40 changes similar to DR have not been described in patients with OSA without diabetes 
suggesting that the presence of hyperglycaemia is mainly responsible for the development of DR but 
OSA might contribute to the progression of the disease. This is supported by our data showing that 
the higher prevalence of DR in patients with OSA vs. those without OSA in our study was mainly 
driven by a higher prevalence of advanced DR but the prevalence of background DR (or early DR) 
was similar in patients with and without OSA; suggesting that OSA contribute to the progression 
rather than the development of the disease. This is biologically plausible, particularly since the 
intermittent hypoxia associated with OSA can result in retinal ischemia and increased VEGF 
production resulting in the development of advanced DR. The lack of OSA effect on maculopathy 
development longitudinally could be due to differences in the pathogenesis between maculopathy 
and pre-/proliferative DR or due to the methods used to diagnose maculopathy in this study (i.e. 
images) rather than the actual measurement of macular thickness using ocular coherence 
tomography. 
Assessing the impact of CPAP treatment on DR and DR progression was not the focus of this study. 
The available observational data, however, suggest that CPAP-compliance might have a favourable 
impact on DR progression although these patients had worse   AHI. The progression to maculopathy 
in the CPAP-compliant group was lower than that in non-compliant group and similar to patients 
with mild OSA. However, it is difficult to assess CPAP efficacy from observational data due to the 
small numbers of patients who were compliant. Nonetheless, these data provide further justification 
for future research to assess the impact of CPAP on the development and progression of DR, and 
highlight the challenges of CPAP compliance in patient with T2D. 
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Our study has several limitations.  We have used home-based portable multi-channel respiratory 
devices rather than in-patient overnight polysomnography.  However, this approach is well 
established.41;42 Our sample population is also drawn from hospital-based diabetes centres-,hence 
we cannot necessarily extend our conclusions to other patient populations.  We have used 2-field 
images to assess DR, rather than 7-field images, which might result in missing peripheral retinal 
lesions. This is unlikely to affect the results unless patients with OSA are more likely develop more 
peripheral lesions compared to patients without OSA (or vice versa), but there is no evidence to 
support this. The limited number of events over the follow-up period did not allow us to perform 
more in depth analysis about the relationship between OSA and DR progression.   
In conclusion, we have identified a relationship between OSA and STDR and maculopathy in patients 
with T2D. OSA was also an independent predictor for the development of advanced DR. There was a 
dose-response relationship between OSA severity and the development of Advanced DR. CPAP-
compliance was associated with reduction in the development of advanced DR. Interventional 
studies are needed to assess the impact of OSA treatment on the development of advanced DR.  
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Figure 1: The study flow diagram. *Represents numbers after excluding patients with the 
condition at baseline in order to assess progression. DR: Diabetic Retinopathy; STDR: Sight 
Threatening DR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Assessed for eligibility (n= 691) 
Excluded (n= 425) 
   Type 1 diabetes (n=108) 
   Known OSA (n=8) 
   Known respiratory disorder, mostly 
asthma or COPD (n=93) 
 End-stage renal disease (n=30) 
   Cancer patients (n=11) 
   Blind (n=9) 
  Declined to participate (n= 166) 
Consented and enrolled in the study 
and had sleep studies and other 
baseline data collected (n=266) 
Excluded (n=36) 
Poor quality sleep studies despite 
repeating (either less than 4 hours or 
loss of leads) (n=30) 
Predominantly Central Sleep Apnea 
(both had severe heart failure) (n=2) 
Patients with no baseline retinal images 
(n=4) 
Baseline cross-sectional analysis 
(n=230) 199 from centre 1 and 31 
from centre 2 
7 patients did not attend follow up visits 
from centre 1 
Patients from centre 2 (n=31) 
 
Study end longitudinal analysis 
164 for progression to advanced DR analysis* 
129 for progression to maculopathy* 
121 for progression to STDR* 
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Table 1: Disease grading protocol in National Guidelines on Screening for Diabetic Retinopathy. 
Retinopathy (R)   
Level 0 None (R0)   
Level 1 Background 
(R1) 
Microaneurysm(s) 
Retinal haemorrhage(s) ± any exudate 
Level 2 Pre-
proliferative 
(R2) 
Venous beading 
Venous loop or reduplication 
Intraretinal microvascular abnormality (IRMA) 
Multiple deep, round or blot haemorrhages 
(CWS—careful search for above features) 
Level 3 Proliferative 
(R3) 
New vessels on disc  
New vessels elsewhere  
Preretinal or vitreous haemorrhage 
Preretinal fibrosis ± tractional retinal detachment 
Maculopathy (M)   
Level 0 M0  
Level 1  M1 Exudate within 1 disc diameter (DD) of the centre of the fovea 
Circinate or group of exudates within the macula 
Retinal thickening within 1 DD of the centre of the fovea (if stereo 
available) 
Any microaneurysm or haemorrhage within 1 DD of the centre of 
the fovea only if associated with a best VA of ≤ (if no stereo) 6/12 
Photocoagulation 
(P) 
 (P1) Focal/grid to macula 
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Table 2: Participant characteristics in relation to OSA status. Data presented mean (SD) or % (n). 
GFR: Glomerular Filtration Rate. Analysis performed using the Chi-square test for categorical 
variables, the independent t test for normally distributed variables and the Mann-Whitney U test for 
non-normally distributed variables. 
 OSA- (n=83) OSA+ (n=147) P value 
Male 41.0% (34) 66.0% (97) <0.001 
White European 38.6% (32) 63.9% (94) <0.001 
Age (years) 54.7 (11.9) 58.7 (11.4) 0.01 
Diabetes duration (years) 10.7 (7.23)  13.1 (7.8)  0.02 
Body Mass Index (kg/m
2
)  31.7 (7.0) 
 
35.8 (8.7)   <0.001 
Waist circumference (cm) 107.1 (15.8) 117.2 (15.9) <0.001 
Systolic blood pressure (mmHg) 125.7 (15.6) 132.6 (17.4) 0.003 
Diastolic blood pressure (mmHg) 77.2 (10.2) 78.3 (10.0) 0.4 
HbA1c (%)  8.1 (1.5) 
 
8.3 (1.3) 0.06 
Total cholesterol (mmol/L) 4.0 (1.1) 3.9 (1.0) 0.54 
Triglycerides (mmol/L) 1.8 (1.2) 
 
2.1 (1.3) 0.04 
Estimated GFR (ml/min/1.73 m
2
) 93.1 (24.7) 82.7 (27.4) 0.008 
Epworth sleepiness score  6.8 (5.7) 9.1 (5.6) 0.004 
Smoking (current or ex-smoker) 38.6% (32) 40.8% (60) 0.74 
Alcohol (consumes alcohol) 14.5% (12) 34.7% (51) 0.001 
Oral hypoglycaemic agents 97.6% (81) 90.5% (133) 0.04 
Thiazolidinediones 14.5% (12) 15.0% (22) 0.92 
Insulin 41.0% (34) 59.9% (88) 0.006 
GLP-1 analogue                 7.2% (6) 13.6% (20) 0.14 
Anti-hypertensive agents 73.5% (61) 85.7% (126) 0.02 
Lipid lowering therapy 85.5% (71) 83.7% (123) 0.71 
Fibrates 4.8% (4) 4.8% (7) 0.9 
Anti-platelet agents 60.2% (50) 71.4% (105) 0.08 
Ischemic heart disease 16.9% (14) 21.8% (32) 0.37 
Diabetic nephropathy  23.8% (19) 50.7% (71) 0.005 
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Table 3: The relationship between OSA status and sight threatening diabetic retinopathy, 
retinopathy and maculopathy (unadjusted analysis). Data presented as % (n) of the respective OSA 
category.   
Total cohort OSA- (n=83) OSA+ (n=147) P values 
Sight threatening diabetic retinopathy* 24.1% (20) 42.9% (63) 0.004 
Advanced retinopathy 7.2% (6) 19.7% (29) 0.01 
Retinopathy R0 45.8% (38) 31.3% (46) 0.03 
R1 47% (39) 49% (72) 
R2 2.4% (2) 8.8% (13) 
R3 4.8% (4) 10.9% (16) 
Maculopathy 19.3% (16) 38.8% (57) 0.002 
South Asians OSA- (n=51) OSA+ (n=53)  
Sight threatening diabetic retinopathy* 27.5% (14) 35.8% (19) 0.36 
Advanced retinopathy 9.8% (5) 15.1% (8) 0.42 
Retinopathy R0 39.2% (20) 26.4% (14) 0.52 
R1 51.0% (26) 58.5% (31) 
R2 3.9% (2) 7.5% (4) 
R3 5.9% (3) 7.5% (4) 
Maculopathy 21.6% (11) 34% (18) 0.16 
White Europeans OSA- (n=32) OSA+ (n=94)  
Sight threatening diabetic retinopathy* 18.8% (6) 46.8% (44) 0.005 
Advanced retinopathy 3.1% (1) 22.3% (21) 0.01 
Retinopathy R0 56.3% (18) 34.0% (32) 0.04 
R1 40.6% (13) 43.6% (41) 
R2 0.0% (0) 9.6% (9) 
R3 3.1% (1) 12.8% (12) 
Maculopathy 15.6% (5) 41.5% (39) 0.01 
*pre-proliferative or proliferative retinopathy, maculopathy or laser treatment 
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Table 4: Assessing the association between OSA and STDR, maculopathy and advanced diabetic 
retinopathy (DR) (R2 or R3) based on the baseline cross-sectional analysis using logistic regression 
models (forced entry method). The odds ratios (OR) reported are the odds for having the outcome 
of interest (STDR, Maculopathy or advanced DR depending on the model) in OSA+ compared to OSA- 
patients. Model 1 is adjusted for OSA, ethnicity, age at diabetes diagnosis, diabetes duration, 
gender, HbA1c, BMI, systolic blood pressure, insulin use, number of anti-hypertensive agents, oral 
anti-hyperglycaemic agents and eGFR. Replacing BMI with waist circumference or waist/hip ratio 
does not change the results significantly. Inserting BMI and waist circumference together into the 
model did not have an impact on the OR.  
Model Nagelkerke 
R Square 
for the 
model 
Odds ratio 95% confidence 
interval 
P value 
Sight Threatening Diabetic Retinopathy*  
Unadjusted: OSA 0.05 2.3 1.3-4.3 0.005 
Model 1 0.32 2.3 1.1-4.9 0.04 
Maculopathy 
Unadjusted: OSA 0.05 2.6 1.4-5.0 0.003 
Model 1 0.28 2.7 1.2-5.9 0.01 
Advanced DR (R2 or R3) 
Unadjusted: OSA 0.05 3.1 1.3-8.0 0.02 
Model 1 0.32 3.0 1.0-9.3 0.06 
*pre-proliferative or proliferative retinopathy, maculopathy or laser treatment) 
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Table 5: The longitudinal impact of OSA on progression to advanced DR (R2 or R3) over the follow 
up period. The odds ratios (OR) reported are the odds for progressing to advanced DR in OSA+ 
compared to OSA- patients and in AHI tertiles 2 and 3 compared to AHI tertile 1 and in ODI tertiles 2 
and 3 compared to tertile 1. The model is adjusted for ethnicity, gender, diabetes duration, age at 
diabetes diagnosis, systolic blood pressure, HbA1c, eGFR, BMI, oral anti-hyperglycaemic agents and 
insulin use and number of anti-hypertensive medications. OSA status (yes/no), OSA status (no, mild, 
moderate to severe), AHI tertiles and ODI tertiles were inserted into the model separately. The AHI 
tertiles were < 4.8 events/hour, 4.8-11.89 events/hour and ≥ 11.90 events/hour for tertiles 1,2 and 3 
respectively. The ODI tertiles were < 4.1 events/hour, ODI 4.1-11.39 events/hour and  ≥ 11.40 
events/hour for ODI tertiles 1,2 and 3 respectively. Nagelkerke R2 for all the 3 models in this table 
was 0.42 
 OR 95% CI P value 
OSA (vs. no OSA) 5.2 1.2-23.0 0.03 
Mild OSA (vs. no OSA) 3.7 0.7-18.0 0.11 
Moderate to severe OSA (vs. no OSA) 14.8 2.3-94.7 0.005 
AHI tertile 2 (vs. tertile 1) 4.0 0.8-19.8 0.09 
AHI tertile 3 (vs. tertile 1) 7.5 1.4-41.3 0.02 
ODI tertile 2 (vs. tertile 1) 3.9 0.8-18.8 0.09 
ODI tertile 3 (vs. tertile 1) 6.0 1.2--31.6 0.03 
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